Comparative Pharmacology
Head-to-head clinical analysis: OMONTYS versus VAFSEO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OMONTYS versus VAFSEO.
OMONTYS vs VAFSEO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythropoiesis-stimulating agent; synthetic peptide agonist of the erythropoietin receptor (EPOR) that stimulates erythropoiesis in red blood cell precursors.
VAFSEO (vadadustat) is a hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor. It stabilizes HIF-α, leading to increased transcription of genes involved in erythropoiesis, including erythropoietin, enhancing red blood cell production.
45 mg subcutaneously once every 4 weeks (monthly) in adults.
Oral: 20 mg three times weekly for 24 weeks.
None Documented
None Documented
Terminal elimination half-life is approximately 14.5 hours in healthy adults; in hemodialysis patients, half-life is extended to 26.4–29.9 hours, supporting weekly dosing.
Terminal half-life is approximately 20-30 hours, supporting once-daily dosing.
Primarily eliminated via the reticuloendothelial system; no significant renal or biliary excretion. The iron component is incorporated into hemoglobin or stored as ferritin/hemosiderin.
Primarily fecal (approximately 81%) and renal (~17%) as unchanged drug and metabolites.
Category C
Category C
Erythropoiesis-Stimulating Agent
Erythropoiesis-Stimulating Agent